tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s

Story Highlights
  • INmune Bio’s Phase 2 trial of XPro™ showed benefits in a specific Alzheimer’s subgroup.
  • XPro™ was well-tolerated and may address neuroinflammation in Alzheimer’s disease.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s

Elevate Your Investing Strategy:

Inmune Bio ( (INMB) ) just unveiled an update.

INmune Bio announced the results of its Phase 2 MINDFuL trial evaluating XPro™ in early Alzheimer’s disease patients with biomarkers of inflammation. While the trial did not meet its primary cognitive endpoint in the overall population, significant benefits were observed in a predefined subgroup of amyloid-positive patients with two or more inflammatory biomarkers. The treatment was well-tolerated, showing potential as a novel approach to addressing neuroinflammation in Alzheimer’s disease. These findings support further development and regulatory engagement for XPro™ as a promising treatment option.

The most recent analyst rating on (INMB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The company has three product platforms, including the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform, which utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases.

Average Trading Volume: 1,451,584

Technical Sentiment Signal: Sell

Current Market Cap: $123.7M

For a thorough assessment of INMB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1